Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 20/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19965818 | 0.84 | CHRM1 (0.48) | CHRM1CHRM5CHRM2CHRM4KCNH2 | |
| SCHEMBL17101358 | 0.80 | CHRM1 (0.42) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL18075926 | 0.80 | CHRM4 (0.40) | CHRM1CHRM5CHRM2CHRM4KCNH2 | |
| SCHEMBL17101492 | 0.80 | CHRM1 (0.40) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL18075912 | 0.79 | CHRM4 (0.43) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL17101344 | 0.79 | CHRM1 (0.41) | CHRM1CHRM5CHRM2CHRM4KCNH2 | |
| SCHEMBL20942004 | 0.79 | CXCR3 (0.34) | CHRM1CHRM5CHRM4KCNH2 | |
| SCHEMBL18075932 | 0.78 | CHRM4 (0.47) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL17101385 | 0.77 | CHRM1 (0.40) | CHRM1CHRM5CHRM2CHRM4KCNH2 | |
| SCHEMBL20942606 | 0.77 | CHRM1 (0.38) | CHRM1CHRM5CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | claimed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | claimed |
| EP-3119396-A1 | MUSCARINIC RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | claimed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ALLERGAN, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-10428088-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ALLERGAN, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10030035-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10030035-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM5 4/4885CHRM2 2/4885 |
| US-10428088-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM5 4/4885CHRM2 2/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM5 4/4885CHRM2 2/4885 |
| US-10030035-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM5 4/4885CHRM2 2/4885 |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ENY2, PNMT, CHRM1 | CHRM1 3/4885CHRM5 41/4885CHRM2 16/4885 |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ENY2, PNMT, CHRM1 | CHRM1 3/4885CHRM5 41/4885CHRM2 16/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM5 4/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.